Member Info for Brumm1875

In the absence of news (let’s wait and see), the -20% share price drop seems to have originated from the US. The stock got hit at the open by a -80k sale which compares to a daily average volume of 40k. It could be a forced seller or someone placing big bets in the options market. Anyway, this high volatility is typical of August time when institutional investors are on holiday and trading is mainly driven by smaller/private investors. Hence, most companies tend to avoid releasing market sensitive news at that time and prefer to wait until September to communicate. Obviously, Management have a duty to release any unexpected news, good or bad, as soon as it is known. Fingers crossed this is not the case today.

RNS just out. The company will give a trading update on Thursday 8th July. Also announced a change of auditors for the financial year 2021/22. Proposal to appoint a new UK based auditor vs Australian previously. It does make sense as the bulk of the business is UK based.

In-depth sector report, covering all companies involved in the covid-19 testing sector. YGEN one of the stocks covered. https://www.proactiveinvestors.co.uk/companies/news/939174/diagnostics-sector-set-to-continue-to-see-growth-in-2021-and-2022-says-broker-finncap-939174.html

$LOAC closed up +6.5% on Nasdaq tonight and currently up +1.5% after hours so up +8.0% overall. Expect 4D to have a good day tomorrow. GLA

Stock up +8% atm, equivalent to £5.80. The London shares have a lot of catching up to do next week. Happy New Year !

Great news announced after hours. Selling the rights for their rare bone disease (OI) treatment in the US & ROW to a US company, Ultragenyx. They will receive $50m upfront and up to $254m in milestones. Mereo keeping the rights for Europe. Royalties for US & ROW in tier double digit %. Furthermore, Ultragenyx will pay for all the phase 2b/3 trial development. At $3 for the ADR, the stock is only back to the equivalent of c. 45p vs year high of c. 60p so plenty of upside left.

The AGM was this morning at 10am. The company has not issued any trading statement or update. Has anyone been following the meeting? Hardly any reaction in the share price so assume nothing significant came out? Thanks

Not sure which share chat is the worst. This one or the one on ADVFN? I expect the same rampers or de-rampers are active in both. Have been a holder for about two years now. It’s been a disappointing share for sure but things might be about turn .... for the better, I hope. Fingers crossed!

The exit of Barder as Chairman is the last piece of the jigsaw in terms of restructuring the BOD. Mark Ward, Innovaderma’s largest shareholder, also a Non exec Director is driving these changes, I believe. The path is now clearer for the new CEO and BOD to outline their strategy and start delivering on the huge growth potential this company has to offer. The AGM, in a couple of weeks time, will be a rubber stamping exercise for all the changes. Expect may be a trading update & possible kitchen sink exercise (get the « bad » news out) and then we’re off! Very positive moves. GLA

On Tuesday, RENX closed down c. -11% on Nasdaq before bouncing +30% yesterday so up c. +15-16% over two days. On AIM the shares were flattish in Wednesday and up +13.5% yesterday so about the same move as Nasdaq over two days. Liquidity on Nasdaq is lower than on AIM, hence the more volatile share price. Overall, both ordinary shares & ADRa moves are correlated with very some small arbitrage opportunities. Closing price is a mid price but including the % spread there is not much of an arbitrage opportunity left.

Of course TickeLad. Mark Ward has patiently built a 15% stake in the business over the past few months, with an average price of between 50p-60p, I guess. Hence, he still has to reap the reward of his investment. As a new Non Executive Director on the BOD, he will have much more influence on the future strategy of Innovaderma. From what I have read on the RNS when he became a Director, he has a great track record of building tech/digital/B2C businesses and creating value for himself and other shareholders. I am happy to see his interest aligned with mine and other shareholders.

AGM to be held on 16th December. I expect an update on current trading and outline of future strategy. With a new CEO & refreshed Board of Directors, there is a clear runway for the share price to take off. Remember, the shares used to trade between 80p and 120p back in 2018-19. My first target is 80p so about 15% upside in the short term. Longer term, who knows but with a market cap of less than £10m for annual sales of £13m and profit of £1.5m (pre covid) the potential is huge. The business should be a big beneficiary of the gradual reopening of the UK & US economies once people get vaccinated late 2020/early 2021. Fill your boots!

Looking at the positives, today’s sell off on the back of the Moderna news (after last week’s Pfizer related sell-off) will flush out the last weak hands. Encouraging to see that we’ve already bounced off the lows.

It is possible but very unlikely. This is a “double blind” trial where neither the patient nor the medical person treating the patient know wether the patient is on the SNG product or placebo. The “treatment” is carried out over a two week period but it takes time to recruit all 100 patients, hence a ramp-up phase of 2 to 3 weeks. Once complete, the data will be an analysed by an independent panel. Overall, the whole process could take up to 2 months. I would expect an RNS next week to update investors on the number of hospitals & patients already on board. Fingers crossed!

The SNG clinical trial is privately funded, using £9m out of the £14m raised a couple of weeks ago. The trials mentioned yesterday as part of the UK Government Recovery Scheme are larger scale trials which are funded with Government/NHS/Public money. The advantages SNG have are: 1) First mover advantage i.e already started 2) Fully funded with shareholders money 3) Smaller scale with 100 patients needed (50 with SNG product, 50 with placebo)
The effect of the treatment is measured over a 2 week period but the ramp up period to have all 100 patients on board means that it will take up to 2 months to collect all the data & carry out the analysis. The upside for SNG shares is if “early” readings from the treatment are very positive, the company would issue an RNS re expanding the trial/collaboration with partners/fast track approval etc.

Hi everyone. I am new to this investors ‘ board but been invested in SNG since January 2019. Bought steadily between 6p and 17p and now watching this stock deliver on its great potential. Took some money out at 30p & 64p but still very long as I believe that a) the current treatment for Covid-19 is one of the most promising around and b) if successful SNG will need partner(s) to mass produce & deliver to patients so a deal/collaboration with a large pharma group is highly likely. AZN would be the obvious partner, of course, but they will now face more competition. Onwards & Upwards!